Advertisement

Topics

J&J moves away from hep C due to rival drugmakers' cures

05:14 EDT 11 Sep 2017 | BioPharmaDive

The big pharma is shuttering its program for JNJ-4178, a hep C combo regimen, as it refocuses R&D investments around hep B treatments.

Original Article: J&J moves away from hep C due to rival drugmakers' cures

NEXT ARTICLE

More From BioPortfolio on "J&J moves away from hep C due to rival drugmakers' cures"

Quick Search
Advertisement